Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab®) for Patients with Non-Hodkin's LymphomaResults of a Prospective Phase I/II StudyDurchführbarkeit und Toxizität einer kombinierten Radioimmuntherapie mit MabThera (Rituximab®) als neue Behandlungsoption für Patienten mit Non-Hodkin-Lymphomen – Ergebnisse einer prospektiven Phase-I/II-Studie

被引:0
|
作者
Alfred Haidenberger*
Sabine Fromm-Haidenberger*
Alexander de Vries
Bela-Andre Popper
Michael Steurer
Ira Skvortsova
Johanna Kantner
Eberhard Gunsilius
Peter Lukas
机构
[1] Medical University Innsbruck,Department of Radiotherapy/Radiooncology
[2] Hospital Gmunden,Institute of Radiology
[3] Hospital Feldkirch,Department of Radiotherapy/Radiooncology
[4] Medical University Innsbruck,Department of Hematology
[5] Hospital Gmunden,Institute of Medical Radiology
关键词
Rituximab; Radiotherapy; Non-Hodgkin's lymphoma; Radio/immunotherapy; Rituximab; Radiotherapie; Non-Hodgkin-Lymphom; Radioimmuntherapie;
D O I
10.1007/s00066-011-2169-y
中图分类号
学科分类号
摘要
引用
收藏
页码:300 / 305
页数:5
相关论文
共 1 条
  • [1] Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (Rituximab®) for Patients with Non-Hodkin's Lymphoma. Results of a Prospective Phase I/II Study
    Haidenberger, Alfred
    Fromm-Haidenberger, Sabine
    de Vries, Alexander
    Popper, Bela-Andre
    Steurer, Michael
    Skvortsova, Ira
    Kantner, Johanna
    Gunsilius, Eberhard
    Lukas, Peter
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (05) : 300 - 305